Aurora secured EU plant variety rights for two proprietary cannabis cultivars, signaling a bigger shift in the market. Protected genetics and consistent outputs are becoming the competitive moat as global medical cannabis matures.

Federal delays in Schedule I research reforms are more than paperwork. They slow cannabis medical legitimacy, dosing standards, and the confidence insurers and mainstream capital need to support the market long term.

Federal seizures can still impact licensed cannabis businesses, even when they follow state rules. Here is why it happens, where operators get exposed, and how to reduce federal friction before it turns into inventory loss.

A recent court decision strengthened cannabis residency requirements in key markets, reshaping who can participate and how deals get structured. Here is what operators need to know to protect market access, partnerships, and expansion plans.

Cannabis is growing, but enforcement history and civil rights narratives still shape regulation, local politics, and business risk. Understanding that context helps operators build stability, trust, and long term resilience.